Clinical Characteristics of Patients Diagnosed with Synthetic Cannabinoid (Bonsai) Intoxication in Intensive Care Unit

Basit Öğe Kaydı
dc.authoridAltinisik, Hatice Betul/0000-0001-9273-0876
dc.contributor.authorAltinisik, Ugur
dc.contributor.authorAltinisik, Hatice Betul
dc.contributor.authorSimsek, Tuncer
dc.contributor.authorDogu, Tugba
dc.contributor.authorSimsek, Esen
dc.contributor.authorAydin, Halide
dc.date.accessioned2025-01-27T21:20:06Z
dc.date.available2025-01-27T21:20:06Z
dc.date.issued2015
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective: In recent years, synthetic cannabinoids (bonsai) poisoning is a widely seen case that needs to be treated in intensive care unit (ICU) in our country. In this study, it was aimed to discuss the clinical characteristics of patients diagnosed with synthetic cannabinoid intoxication followed in ICU. Material and Method: Patients followed in ICU of Canakkale Onsekiz Mart University and Canakkale State Hospital between 2014 and 2015 were studied retrospectively. Results: Twelve cases were included. In neurological system; confusions (n=4), drowsiness (n=7), restlessness/agitations (n=5), hallucinations (n=2), anxieties/panics (n=3), acute psychosis (n=1) and amnesias (n=11) were detected. One patient was intubated. In cardiovascular system; tachycardias (n=3), bradycardias (n=2), hypertensions (n=2), hypotension (n=1), and arrhythmias (n=2) were observed. In laboratory tests, leukocytosis (n=4), leukopenia (n=1), hypoglycemias (n=3), elevation in liver and renal function tests (n=1) were identified. The average recovery time was 19.3-hours and the average ICU stay was 3-days. Conclusion: In the synthetic cannabinoid intoxication cases; it should be kept in mind that seizure activities may occur in the first hours, myocardial infarction risk in the first 3-days. Liver-kidney functions should be monitored. Hypopotasemia is the most common electrolyte disorder. Cases without any complication are expected to recover in 24-hours. However, new types of synthetic cannabinoids are put on the market every day.
dc.identifier.doi10.4274/tybdd.36025
dc.identifier.endpage121
dc.identifier.issn2146-6416
dc.identifier.issn2147-267X
dc.identifier.issue3
dc.identifier.startpage117
dc.identifier.urihttps://doi.org/10.4274/tybdd.36025
dc.identifier.urihttps://hdl.handle.net/20.500.12428/28818
dc.identifier.volume13
dc.identifier.wosWOS:000422271200004
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isotr
dc.publisherGalenos Yayincilik
dc.relation.ispartofJournal of The Turkish Society of Intensive Care-Turk Yogun Bakm Dernegi Dergisi
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectBonsai
dc.subjectsynthetic cannabinoid
dc.subjectintensive care unit
dc.titleClinical Characteristics of Patients Diagnosed with Synthetic Cannabinoid (Bonsai) Intoxication in Intensive Care Unit
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu